Alternative  ||| S:0 E:12 ||| JJ
paths  ||| S:12 E:18 ||| NNS
in  ||| S:18 E:21 ||| IN
HIV-1  ||| S:21 E:27 ||| NNP
targeted  ||| S:27 E:36 ||| VBD
human  ||| S:36 E:42 ||| JJ
signal  ||| S:42 E:49 ||| NN
transduction  ||| S:49 E:62 ||| FW
pathways  ||| S:62 E:71 ||| FW
Human  ||| S:71 E:77 ||| FW
immunodeficiency  ||| S:77 E:94 ||| FW
virus-1  ||| S:94 E:102 ||| FW
( ||| S:102 E:103 ||| -LRB-
HIV-1 ||| S:103 E:108 ||| NNP
)  ||| S:108 E:110 ||| -RRB-
has  ||| S:110 E:114 ||| VBZ
a  ||| S:114 E:116 ||| DT
minimal  ||| S:116 E:124 ||| JJ
genome  ||| S:124 E:131 ||| NN
of  ||| S:131 E:134 ||| IN
only  ||| S:134 E:139 ||| RB
9  ||| S:139 E:141 ||| CD
genes ||| S:141 E:146 ||| NNS
,  ||| S:146 E:148 ||| ,
which  ||| S:148 E:154 ||| WDT
encode  ||| S:154 E:161 ||| VBD
15  ||| S:161 E:164 ||| CD
proteins ||| S:164 E:172 ||| NNS
.  ||| S:172 E:174 ||| .
HIV-1  ||| S:174 E:180 ||| NNP
thus  ||| S:180 E:185 ||| RB
depends  ||| S:185 E:193 ||| VBZ
on  ||| S:193 E:196 ||| IN
the  ||| S:196 E:200 ||| DT
human  ||| S:200 E:206 ||| JJ
host  ||| S:206 E:211 ||| NN
for  ||| S:211 E:215 ||| IN
virtually  ||| S:215 E:225 ||| RB
every  ||| S:225 E:231 ||| DT
aspect  ||| S:231 E:238 ||| NN
of  ||| S:238 E:241 ||| IN
its  ||| S:241 E:245 ||| PRP$
life  ||| S:245 E:250 ||| NN
cycle ||| S:250 E:255 ||| NN
.  ||| S:255 E:257 ||| .
The  ||| S:257 E:261 ||| DT
universal  ||| S:261 E:271 ||| JJ
language  ||| S:271 E:280 ||| NN
of  ||| S:280 E:283 ||| IN
communication  ||| S:283 E:297 ||| NN
in  ||| S:297 E:300 ||| IN
biological  ||| S:300 E:311 ||| JJ
systems ||| S:311 E:318 ||| NNS
,  ||| S:318 E:320 ||| ,
including  ||| S:320 E:330 ||| VBG
between  ||| S:330 E:338 ||| IN
pathogen  ||| S:338 E:347 ||| NN
and  ||| S:347 E:351 ||| CC
host ||| S:351 E:355 ||| NN
,  ||| S:355 E:357 ||| ,
is  ||| S:357 E:360 ||| VBZ
via  ||| S:360 E:364 ||| IN
signal  ||| S:364 E:371 ||| NN
transduction  ||| S:371 E:384 ||| NN
pathways ||| S:384 E:392 ||| NN
.  ||| S:392 E:394 ||| .
The  ||| S:394 E:398 ||| DT
fundamental  ||| S:398 E:410 ||| JJ
units  ||| S:410 E:416 ||| NNS
of  ||| S:416 E:419 ||| IN
these  ||| S:419 E:425 ||| DT
pathways  ||| S:425 E:434 ||| NNS
are  ||| S:434 E:438 ||| VBP
protein  ||| S:438 E:446 ||| JJ
protein  ||| S:446 E:454 ||| NN
interactions ||| S:454 E:466 ||| NNS
.  ||| S:466 E:468 ||| .
Understanding  ||| S:468 E:482 ||| VBG
the  ||| S:482 E:486 ||| DT
functional  ||| S:486 E:497 ||| JJ
significance  ||| S:497 E:510 ||| NN
of  ||| S:510 E:513 ||| IN
HIV-1 ||| S:513 E:518 ||| NNP
,  ||| S:518 E:520 ||| ,
human  ||| S:520 E:526 ||| JJ
interactions  ||| S:526 E:539 ||| NN
requires  ||| S:539 E:548 ||| VBZ
viewing  ||| S:548 E:556 ||| VBG
them  ||| S:556 E:561 ||| PRP
in  ||| S:561 E:564 ||| IN
the  ||| S:564 E:568 ||| DT
context  ||| S:568 E:576 ||| NN
of  ||| S:576 E:579 ||| IN
human  ||| S:579 E:585 ||| JJ
signal  ||| S:585 E:592 ||| NN
transduction  ||| S:592 E:605 ||| NN
pathways ||| S:605 E:613 ||| NN
.  ||| S:613 E:615 ||| .
Integration  ||| S:615 E:627 ||| NN
of  ||| S:627 E:630 ||| IN
HIV-1 ||| S:630 E:635 ||| NNP
,  ||| S:635 E:637 ||| ,
human  ||| S:637 E:643 ||| JJ
interactions  ||| S:643 E:656 ||| NNS
with  ||| S:656 E:661 ||| IN
known  ||| S:661 E:667 ||| JJ
signal  ||| S:667 E:674 ||| NN
transduction  ||| S:674 E:687 ||| NN
pathways  ||| S:687 E:696 ||| NN
indicates  ||| S:696 E:706 ||| VBZ
that  ||| S:706 E:711 ||| IN
the  ||| S:711 E:715 ||| DT
majority  ||| S:715 E:724 ||| NN
of  ||| S:724 E:727 ||| IN
known  ||| S:727 E:733 ||| VBN
human  ||| S:733 E:739 ||| JJ
pathways  ||| S:739 E:748 ||| NNS
have  ||| S:748 E:753 ||| VBP
the  ||| S:753 E:757 ||| DT
potential  ||| S:757 E:767 ||| JJ
to  ||| S:767 E:770 ||| TO
be  ||| S:770 E:773 ||| VB
effected  ||| S:773 E:782 ||| VBN
through  ||| S:782 E:790 ||| IN
at  ||| S:790 E:793 ||| IN
least  ||| S:793 E:799 ||| JJS
one  ||| S:799 E:803 ||| CD
interaction  ||| S:803 E:815 ||| NN
with  ||| S:815 E:820 ||| IN
an  ||| S:820 E:823 ||| DT
HIV-1  ||| S:823 E:829 ||| NNP
protein  ||| S:829 E:837 ||| NN
at  ||| S:837 E:840 ||| IN
some  ||| S:840 E:845 ||| DT
point  ||| S:845 E:851 ||| NN
during  ||| S:851 E:858 ||| IN
the  ||| S:858 E:862 ||| DT
HIV-1  ||| S:862 E:868 ||| NNP
life  ||| S:868 E:873 ||| NN
cycle ||| S:873 E:878 ||| NN
.  ||| S:878 E:880 ||| .
For  ||| S:880 E:884 ||| IN
each  ||| S:884 E:889 ||| DT
pathway ||| S:889 E:896 ||| NN
,  ||| S:896 E:898 ||| ,
we  ||| S:898 E:901 ||| PRP
define  ||| S:901 E:908 ||| VB
simple  ||| S:908 E:915 ||| JJ
paths  ||| S:915 E:921 ||| NNS
between  ||| S:921 E:929 ||| IN
start  ||| S:929 E:935 ||| NN
points  ||| S:935 E:942 ||| NNS
( ||| S:942 E:943 ||| -LRB-
i.e.  ||| S:943 E:948 ||| FW
no  ||| S:948 E:951 ||| DT
edges  ||| S:951 E:957 ||| NNS
going  ||| S:957 E:963 ||| VBG
into  ||| S:963 E:968 ||| IN
a  ||| S:968 E:970 ||| DT
node ||| S:970 E:974 ||| NN
)  ||| S:974 E:976 ||| -RRB-
and  ||| S:976 E:980 ||| CC
end  ||| S:980 E:984 ||| NN
points  ||| S:984 E:991 ||| NNS
( ||| S:991 E:992 ||| -LRB-
i.e.  ||| S:992 E:997 ||| FW
no  ||| S:997 E:1000 ||| FW
edges  ||| S:1000 E:1006 ||| FW
leaving  ||| S:1006 E:1014 ||| FW
a  ||| S:1014 E:1016 ||| FW
node ||| S:1016 E:1020 ||| FW
) ||| S:1020 E:1021 ||| -RRB-
.  ||| S:1021 E:1023 ||| .
We  ||| S:1023 E:1026 ||| PRP
then  ||| S:1026 E:1031 ||| RB
identify  ||| S:1031 E:1040 ||| VB
the  ||| S:1040 E:1044 ||| DT
paths  ||| S:1044 E:1050 ||| NNS
that  ||| S:1050 E:1055 ||| WDT
pass  ||| S:1055 E:1060 ||| VBP
through  ||| S:1060 E:1068 ||| IN
human  ||| S:1068 E:1074 ||| JJ
proteins  ||| S:1074 E:1083 ||| NNS
that  ||| S:1083 E:1088 ||| IN
interact  ||| S:1088 E:1097 ||| NN
with  ||| S:1097 E:1102 ||| IN
HIV-1  ||| S:1102 E:1108 ||| CD
proteins ||| S:1108 E:1116 ||| NNS
.  ||| S:1116 E:1118 ||| .
We  ||| S:1118 E:1121 ||| PRP
supplement  ||| S:1121 E:1132 ||| VB
the  ||| S:1132 E:1136 ||| DT
combined  ||| S:1136 E:1145 ||| JJ
map  ||| S:1145 E:1149 ||| NN
with  ||| S:1149 E:1154 ||| IN
functional  ||| S:1154 E:1165 ||| JJ
information ||| S:1165 E:1176 ||| NN
,  ||| S:1176 E:1178 ||| ,
including  ||| S:1178 E:1188 ||| VBG
which  ||| S:1188 E:1194 ||| WDT
proteins  ||| S:1194 E:1203 ||| NNS
are  ||| S:1203 E:1207 ||| VBP
known  ||| S:1207 E:1213 ||| VBN
drug  ||| S:1213 E:1218 ||| NN
targets  ||| S:1218 E:1226 ||| NNS
and  ||| S:1226 E:1230 ||| CC
which  ||| S:1230 E:1236 ||| WDT
proteins  ||| S:1236 E:1245 ||| NNS
contribute  ||| S:1245 E:1256 ||| VBP
significantly  ||| S:1256 E:1270 ||| RB
to  ||| S:1270 E:1273 ||| TO
HIV-1  ||| S:1273 E:1279 ||| CD
function  ||| S:1279 E:1288 ||| NN
as  ||| S:1288 E:1291 ||| IN
revealed  ||| S:1291 E:1300 ||| NN
by  ||| S:1300 E:1303 ||| IN
recent  ||| S:1303 E:1310 ||| JJ
siRNA  ||| S:1310 E:1316 ||| JJ
screens ||| S:1316 E:1323 ||| NNS
.  ||| S:1323 E:1325 ||| .
We  ||| S:1325 E:1328 ||| PRP
find  ||| S:1328 E:1333 ||| VBP
that  ||| S:1333 E:1338 ||| IN
there  ||| S:1338 E:1344 ||| EX
are  ||| S:1344 E:1348 ||| VBP
often  ||| S:1348 E:1354 ||| RB
alternative  ||| S:1354 E:1366 ||| JJ
paths  ||| S:1366 E:1372 ||| NNS
starting  ||| S:1372 E:1381 ||| VBG
and  ||| S:1381 E:1385 ||| CC
ending  ||| S:1385 E:1392 ||| VBG
at  ||| S:1392 E:1395 ||| IN
the  ||| S:1395 E:1399 ||| DT
same  ||| S:1399 E:1404 ||| JJ
proteins  ||| S:1404 E:1413 ||| NNS
but  ||| S:1413 E:1417 ||| CC
circumventing  ||| S:1417 E:1431 ||| VBG
the  ||| S:1431 E:1435 ||| DT
intermediate  ||| S:1435 E:1448 ||| JJ
steps  ||| S:1448 E:1454 ||| NNS
disrupted  ||| S:1454 E:1464 ||| VBN
by  ||| S:1464 E:1467 ||| IN
HIV-1 ||| S:1467 E:1472 ||| NNP
.  ||| S:1472 E:1474 ||| .
A  ||| S:1474 E:1476 ||| DT
mapping  ||| S:1476 E:1484 ||| NN
of  ||| S:1484 E:1487 ||| IN
HIV-1 ||| S:1487 E:1492 ||| NNP
,  ||| S:1492 E:1494 ||| ,
human  ||| S:1494 E:1500 ||| JJ
interactions  ||| S:1500 E:1513 ||| NNS
to  ||| S:1513 E:1516 ||| TO
human  ||| S:1516 E:1522 ||| JJ
signal  ||| S:1522 E:1529 ||| NN
transduction  ||| S:1529 E:1542 ||| NN
pathways  ||| S:1542 E:1551 ||| NN
is  ||| S:1551 E:1554 ||| VBZ
presented  ||| S:1554 E:1564 ||| VBN
here  ||| S:1564 E:1569 ||| RB
to  ||| S:1569 E:1572 ||| TO
link  ||| S:1572 E:1577 ||| VB
interactions  ||| S:1577 E:1590 ||| VBN
with  ||| S:1590 E:1595 ||| IN
functions ||| S:1595 E:1604 ||| NNS
.  ||| S:1604 E:1606 ||| .
We  ||| S:1606 E:1609 ||| PRP
proposed  ||| S:1609 E:1618 ||| VBD
a  ||| S:1618 E:1620 ||| DT
new  ||| S:1620 E:1624 ||| JJ
way  ||| S:1624 E:1628 ||| NN
of  ||| S:1628 E:1631 ||| IN
analyzing  ||| S:1631 E:1641 ||| VBG
the  ||| S:1641 E:1645 ||| DT
virus  ||| S:1645 E:1651 ||| NN
host  ||| S:1651 E:1656 ||| NN
interactions  ||| S:1656 E:1669 ||| NNS
by  ||| S:1669 E:1672 ||| IN
identifying  ||| S:1672 E:1684 ||| VBG
HIV-1  ||| S:1684 E:1690 ||| NNP
targets  ||| S:1690 E:1698 ||| VBZ
as  ||| S:1698 E:1701 ||| RB
well  ||| S:1701 E:1706 ||| RB
as  ||| S:1706 E:1709 ||| IN
alternative  ||| S:1709 E:1721 ||| JJ
paths  ||| S:1721 E:1727 ||| NNS
bypassing  ||| S:1727 E:1737 ||| VBP
the  ||| S:1737 E:1741 ||| DT
HIV-1  ||| S:1741 E:1747 ||| NNP
targeted  ||| S:1747 E:1756 ||| VBD
steps ||| S:1756 E:1761 ||| NNS
.  ||| S:1761 E:1763 ||| .
This  ||| S:1763 E:1768 ||| DT
approach  ||| S:1768 E:1777 ||| NN
yields  ||| S:1777 E:1784 ||| NNS
numerous  ||| S:1784 E:1793 ||| JJ
experimentally  ||| S:1793 E:1808 ||| JJ
testable  ||| S:1808 E:1817 ||| JJ
hypotheses  ||| S:1817 E:1828 ||| NN
on  ||| S:1828 E:1831 ||| IN
how  ||| S:1831 E:1835 ||| WRB
HIV-1  ||| S:1835 E:1841 ||| NNP
function  ||| S:1841 E:1850 ||| NN
may  ||| S:1850 E:1854 ||| MD
be  ||| S:1854 E:1857 ||| VB
compromised  ||| S:1857 E:1869 ||| VBN
and  ||| S:1869 E:1873 ||| CC
human  ||| S:1873 E:1879 ||| JJ
cellular  ||| S:1879 E:1888 ||| JJ
function  ||| S:1888 E:1897 ||| NN
restored  ||| S:1897 E:1906 ||| VBN
by  ||| S:1906 E:1909 ||| IN
pharmacological  ||| S:1909 E:1925 ||| JJ
approaches ||| S:1925 E:1935 ||| NNS
.  ||| S:1935 E:1937 ||| .
We  ||| S:1937 E:1940 ||| PRP
are  ||| S:1940 E:1944 ||| VBP
making  ||| S:1944 E:1951 ||| VBG
the  ||| S:1951 E:1955 ||| DT
full  ||| S:1955 E:1960 ||| JJ
set  ||| S:1960 E:1964 ||| NN
of  ||| S:1964 E:1967 ||| IN
pathway  ||| S:1967 E:1975 ||| JJ
analysis  ||| S:1975 E:1984 ||| NN
results  ||| S:1984 E:1992 ||| NNS
available  ||| S:1992 E:2002 ||| JJ
to  ||| S:2002 E:2005 ||| TO
the  ||| S:2005 E:2009 ||| DT
community ||| S:2009 E:2018 ||| NN
.  ||| S:2018 E:2020 ||| .
